Overall, these data suggest that BTK inhibition via ibrutinib diminishes TREM-1-mediated PMN function, providing a potential clinical strategy for modulating immune responses driven by TREM-1, such as those involved in sepsis, inflammatory bowel disease, peripheral artery disease, and psoriasis [126,127]. The gene discussed is TREM1; the disease is peripheral arterial disease.